4.03
Schlusskurs vom Vortag:
$3.79
Offen:
$3.83
24-Stunden-Volumen:
72,306
Relative Volume:
0.53
Marktkapitalisierung:
$43.46M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-19.09M
KGV:
-2.264
EPS:
-1.78
Netto-Cashflow:
$-17.24M
1W Leistung:
+7.18%
1M Leistung:
+26.73%
6M Leistung:
-10.04%
1J Leistung:
-12.77%
Lantern Pharma Inc Stock (LTRN) Company Profile
Firmenname
Lantern Pharma Inc
Sektor
Branche
Telefon
972-277-1136
Adresse
1920 MCKINNEY AVENUE, DALLAS, TX
Vergleichen Sie LTRN mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
LTRN
Lantern Pharma Inc
|
4.03 | 40.55M | 0 | -19.09M | -17.24M | -1.78 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Lantern Pharma Inc Stock (LTRN) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2021-10-07 | Eingeleitet | H.C. Wainwright | Buy |
Lantern Pharma Inc Aktie (LTRN) Neueste Nachrichten
Is Lantern Pharma Inc. a good long term investmentTriple-digit returns - jammulinksnews.com
What drives Lantern Pharma Inc. stock priceFree Risk Assessment Services - Autocar Professional
Lantern Pharma Inc. Stock Analysis and ForecastBreakthrough capital growth - jammulinksnews.com
Lantern Pharma (NASDAQ: LTRN) Secures EU Patent For AI-Designed Cancer Drug LP-284 - Barchart.com
What analysts say about Lantern Pharma Inc. stockFastest-growing stock picks - Autocar Professional
Lantern Pharma secures EU patent for AI-driven cancer drug LP-284 - MSN
Lantern Pharma Secures EU Patent Allowance for LP-284, Bolstering Global IP Position for AI-Developed Cancer Therapy - BioSpace
Lantern Pharma (LTRN) Secures EU Patent for Cancer Drug LP-284 - GuruFocus
Lantern Pharma (LTRN) Gains Patent Approval for Key Drug in Euro - GuruFocus
Lantern Pharma Unveils AI Module for Predicting Cancer Treatment Efficacy - AInvest
Lantern Pharma (NASDAQ: LTRN) Launches AI Module to Accelerate Development of Targeted Cancer Combination Therapies - The Globe and Mail
IBN Initiates Coverage of Lantern Pharma Inc. - GlobeNewswire
Lantern Pharma Initiates Coverage with IBN, Aims to Revolutionize Oncology Drug Development - AInvest
Why Lantern Pharma Inc. stock attracts strong analyst attentionFree Stock Movement Tracking - Newser
How Lantern Pharma Inc. stock performs during market volatilityInvestor Friendly Risk Reward - Newser
Lantern Pharma Inc. Unveils AI-Powered Module to Predict Activity and Efficacy of Combination Regimens in Clinical Cancer Treatment - MarketScreener
Lantern Pharma launches AI module to predict cancer treatment combos - Investing.com India
Lantern Pharma (LTRN) Launches AI Module for Cancer Treatment Ad - GuruFocus
Lantern Pharma launches AI module to predict cancer treatment combos By Investing.com - Investing.com South Africa
Lantern Pharma Unveils Groundbreaking AI-Powered Module to Predict Activity and Efficacy of Combination Regimens in Clinical Cancer Treatment - Business Wire
What makes Lantern Pharma Inc. stock price move sharplyFree Access to Community - Newser
LTRN Stock Price and Chart — NASDAQ:LTRN - TradingView
Lantern Pharma Enters ATM Sales Agreement with ThinkEquity - TipRanks
Why Lantern Pharma (NASDAQ: LTRN) Is ‘One to Watch’ - The Globe and Mail
Why Lantern Pharma (NASDAQ: LTRN) Is ‘One To Watch’ - Barchart.com
Lantern Pharma Inc. Harnesses AI to Revolutionize Oncology Drug Development - citybuzz -
Lantern Pharma’s (NASDAQ: LTRN) AI-Powered Platform Delivers Promising and Durable Results in Lung Cancer Trial - Barchart.com
Lantern Pharma (NASDAQ: LTRN) Reports Complete Response in Advanced NSCLC Patient in HARMONIC(TM) Trial - The Globe and Mail
Lantern Pharma Inc. Reports Complete Response in Advanced NSCLC Patient in HARMONIC(TM) Trial - citybuzz -
Lung Cancer Patient in Lantern Pharma's Harmonic Trial Shows Durable Complete Response in Target Cancer Lesions with Survival Continuing for Nearly Two Years | LTRN Stock News - GuruFocus
Lung Cancer Patient In Lantern Pharma's Harmonic Trial Shows Durable Complete Response In Target Cancer Lesions With Survival Continuing For Nearly Two Years - MarketScreener
Lung Cancer Patient in Lantern Pharma’s Harmonic Trial Shows Durable Complete Response in Target Cancer Lesions with Survival Continuing for Nearly Two Years - Yahoo Finance
Two Sigma Investments LP Sells 17,795 Shares of Lantern Pharma Inc. (NASDAQ:LTRN) - Defense World
Lantern Pharma shares sold by major shareholder for $123,600 - Investing.com South Africa
Finanzdaten der Lantern Pharma Inc-Aktie (LTRN)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):